Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Gyre Therapeutics, Inc. - Common Stock (NQ: GYRE ) 13.12 -0.72 (-5.20%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Gyre Therapeutics, Inc. - Common Stock Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update November 13, 2024 From Gyre Therapeutics, Inc. Via GlobeNewswire Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis October 22, 2024 From Gyre Therapeutics, Inc. Via GlobeNewswire Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference October 01, 2024 From Gyre Therapeutics, Inc. Via GlobeNewswire Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 04, 2024 From Gyre Therapeutics, Inc. Via GlobeNewswire Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update August 13, 2024 From Gyre Therapeutics, Inc. Via GlobeNewswire Gyre Therapeutics to Present at Sidoti Virtual Investor Conference August 09, 2024 From Gyre Therapeutics, Inc. Via GlobeNewswire Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors August 08, 2024 From Gyre Therapeutics, Inc. Via GlobeNewswire Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia July 02, 2024 From Gyre Therapeutics, Inc. Via GlobeNewswire Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology June 18, 2024 From Gyre Therapeutics, Inc. Via GlobeNewswire Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension May 30, 2024 From Gyre Therapeutics, Inc. Via GlobeNewswire Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes May 28, 2024 From Gyre Therapeutics, Inc. Via GlobeNewswire Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Gyre Therapeutics, Inc. Via GlobeNewswire Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update March 26, 2024 From Gyre Therapeutics, Inc. Via GlobeNewswire Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum March 21, 2024 From Gyre Therapeutics, Inc. Via GlobeNewswire Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting November 13, 2023 From Gyre Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
